Literature DB >> 1773024

Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?

Y Horsmans1, J P Desager, C Harvengt.   

Abstract

A link between debrisoquine oxidation phenotype and lung cancer susceptibility has been evoked by some authors but not confirmed by others. For this reason, we compared the frequency of debrisoquine poor metabolizer phenotype in 91 Belgian patients with lung cancer to that studied in 167 healthy Belgian subjects. No significant difference was observed in our study. These results do not support the existence of this link.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1773024     DOI: 10.1016/0753-3322(91)90066-3

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  1 in total

1.  The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

Authors:  P M Christensen; P C Gøtzsche; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.